In a report released on January 19, David Nierengarten from Wedbush maintained a Buy rating on Ikena Oncology (IKNA – Research Report), with a price target of $8.00. The company’s shares opened today at $1.54.
According to TipRanks, Nierengarten is a 5-star analyst with an average return of 11.5% and a 43.76% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as Bluebird Bio, Oric Pharmaceuticals, and Vor Biopharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ikena Oncology with a $9.50 average price target, representing a 516.88% upside. In a report released on January 19, H.C. Wainwright also maintained a Buy rating on the stock with a $11.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $7.64 and a one-year low of $1.02. Currently, Ikena Oncology has an average volume of 212.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ikena Oncology (IKNA) Company Description:
Ikena Oncology Inc is an oncology company. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The company is advancing five clinical, preclinical and discovery programs: IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme Kynase; discovery-stage molecules targeting the Hippo signaling pathway; and a discovery-stage program against an undisclosed target.
Read More on IKNA:
